Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.57 |
| ▸ | CTSK | P43235 | 7/20 | 0.57 |
| ▸ | CTSB | P07858 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9888267 | 0.93 | PPARA (0.54) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6572493 | 0.93 | PPARA (0.54) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL23447154 | 0.92 | CTSS (0.54) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL27487988 | 0.89 | CTSS (0.65) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL16163459 | 0.89 | CTSS (0.63) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL3821800 | 0.89 | CTSS (0.65) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL27487987 | 0.89 | CTSS (0.65) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL7235877 | 0.89 | CTSS (0.63) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL1486267 | 0.89 | CTSS (0.63) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL23069526 | 0.88 | CTSS (0.63) | CTSSCTSKCTSBCTSLREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM LTD (IL) | 2022-11-17 | — | — | US | disclosed |
| EP-4025200-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | Neuroderm Ltd (IL) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021044420-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | DAO, DDC, AADAT | CTSS 1408/4885CTSK 1616/4885CTSB 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.